Successful Treatment of Bexarotene-Induced Central Hypothyroidism
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society..
The synthetic retinoid bexarotene (BXT), used in the treatment of cutaneous T-cell lymphoma (CTCL), has been associated with central hypothyroidism due to suppression of thyrotropin (TSH) secretion and upregulation of peripheral thyroxine (T4) and triiodothyronine (T3) metabolism. We present a case of a 41-year-old man with CTCL who developed central hypothyroidism within 1 month of receiving BXT. He required sequential uptitration of levothyroxine (LT4) over 15 months, and free T4 (FT4) and total T3 levels were normalized by a daily regimen of LT4 600 mcg and liothyronine (LT3) 15 mcg. While almost all patients regain normal hypothalamic-pituitary-thyroid axis function after cessation of BXT, there are limited data regarding LT4 and LT3 dosing required to adequately treat central hypothyroidism in patients on BXT. Our patient required an LT4 dose approximately 2.8 times the calculated weight-based dose and LT3 supplementation, demonstrating a large LT4/LT3 combination dose may be required to compensate for BXT-induced central hypothyroidism.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
JCEM case reports - 2(2024), 4 vom: 20. Apr., Seite luae041 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tucci, Marissa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bexarotene |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1210/jcemcr/luae041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370524934 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370524934 | ||
| 003 | DE-627 | ||
| 005 | 20240404000359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240403s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/jcemcr/luae041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM370524934 | ||
| 035 | |a (NLM)38562989 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tucci, Marissa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful Treatment of Bexarotene-Induced Central Hypothyroidism |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a The synthetic retinoid bexarotene (BXT), used in the treatment of cutaneous T-cell lymphoma (CTCL), has been associated with central hypothyroidism due to suppression of thyrotropin (TSH) secretion and upregulation of peripheral thyroxine (T4) and triiodothyronine (T3) metabolism. We present a case of a 41-year-old man with CTCL who developed central hypothyroidism within 1 month of receiving BXT. He required sequential uptitration of levothyroxine (LT4) over 15 months, and free T4 (FT4) and total T3 levels were normalized by a daily regimen of LT4 600 mcg and liothyronine (LT3) 15 mcg. While almost all patients regain normal hypothalamic-pituitary-thyroid axis function after cessation of BXT, there are limited data regarding LT4 and LT3 dosing required to adequately treat central hypothyroidism in patients on BXT. Our patient required an LT4 dose approximately 2.8 times the calculated weight-based dose and LT3 supplementation, demonstrating a large LT4/LT3 combination dose may be required to compensate for BXT-induced central hypothyroidism | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a bexarotene | |
| 650 | 4 | |a central hypothyroidism | |
| 650 | 4 | |a levothyroxine | |
| 650 | 4 | |a liothyronine | |
| 700 | 1 | |a Galagan, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Lovre, Dragana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCEM case reports |d 2023 |g 2(2024), 4 vom: 20. Apr., Seite luae041 |w (DE-627)NLM357254589 |x 2755-1520 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2024 |g number:4 |g day:20 |g month:04 |g pages:luae041 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/jcemcr/luae041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2024 |e 4 |b 20 |c 04 |h luae041 | ||